Novo Nordisk India Introduces Ozempic, Considering Socio-Economic Factors | Briefs

Novo Nordisk has officially launched Ozempic in India, a once-weekly GLP-1 receptor agonist for adults managing uncontrolled type 2 diabetes. Intended as an add-on therapy to diet and exercise, Ozempic arrives as India grapples with a rapidly increasing diabetes burden and generalized obesity.

Novo Nordisk Introduces Ozempic in India

Novo Nordisk has officially launched Ozempic (injectable semaglutide) in India. This marks the availability of a widely used once-weekly GLP-1 receptor agonist for adults dealing with uncontrolled type 2 diabetes. The company stated that Ozempic® is designed to supplement diet and exercise, arriving at a crucial time for India, which is experiencing a surge in diabetes cases.

According to WHO's 2023-24 estimates, India has 101 million individuals living with diabetes. An additional 136 million are classified as prediabetic, and 254 million are affected by generalized obesity. These figures underscore the pressing need for effective treatment solutions. Health tracking apps like Shotlee can help monitor blood sugar levels and medication adherence.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

Novo Nordisk India MD Vikrant Shrotriya pointed out that many patients face the dual challenge of diabetes and excess weight, making Ozempic a suitable therapeutic option. He also noted that the company is aware of India's socioeconomic realities. To improve accessibility, the medication has been priced at Rs 2,200 per week.

Source Information

Originally published by The Times of India.Read the original article →

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Health & Wellness

What's the Deal with Peptides? The Hyped Market Under FDA Review

An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.

8 min read

Health & Wellness

Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program

Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.

8 min read

Medical Research

Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials

Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.

7 min read

Same topic: Diabetes

All Diabetes articles →

Pharmaceutical Industry News

Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics

Samsung Biologics has announced a major acquisition of PolyPeptide Group AG for $1.8 billion, marking a strategic expansion into the rapidly growing peptide therapeutics market, particularly for GLP-1 drugs.

8 min read

Weight Management

Semaglutide for Weight Loss in Adults Over 65: New Study Findings

A recent analysis of the STEP trials reveals that semaglutide, the active ingredient in popular medications like Ozempic and Wegovy, offers significant weight loss and health benefits for adults over 65 with obesity, with a safety profile comparable to younger populations.

8 min read

Health

Fat Jabs Slash Alcohol-Related Hospitalisations by More Than a Quarter

Recent analysis indicates that GLP-1 weight loss medications significantly reduce the risk of alcohol-related hospital admissions by approximately 26 percent compared to other diabetes treatments.

8 min read

More in Health

Health

Ozempic, a Diabetes Medication, Slated for India Launch This Month

Novo Nordisk is set to introduce Ozempic in India, complementing their existing semaglutide product line. This launch occurs amidst strong competition from Eli Lilly's Mounjaro. The new medication may also be prescribed for other health conditions.

1 min read

Health

Anticipating Large Profits: Ozempic Patent Expiration Sparks Indian Pharma Generics Race

With the impending expiration of the Ozempic and Wegovy patents, Indian pharmaceutical giants are gearing up for a significant opportunity in the generics market. Surging obesity rates across India are fueling the demand for affordable weight-loss solutions.

7 min read

Health

Mounjaro Weight-Loss Injection Now Top-Selling Drug in India

According to recent data, Mounjaro, a drug for obesity and diabetes developed by Eli Lilly, has emerged as India's top-selling pharmaceutical brand. The medication's sales have surpassed those of long-time market leader Augmentin.

3 min read